Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768389 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT02768389: Completed Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
NCT02768389 is a Early Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02768389, a Early Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab. This research study involves bevacizumab in combination with a special diet called the Modified Atkins Diet (MAD). The purpose of this study is to research if patients can stay on the MAD when it is added to the standard bevacizumab treatment.
Primary Outcome
The number of patients following a Modified Atkins Diet for at least 80% of the time as a measure of feasibility
Interventions
- DRUG Bevacizumab
- BEHAVIORAL Modified Atkins Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09-06 |
| Est. Completion | 2018-11 |
| Phase | Early Phase 1 |
What the finished NCT02768389 record still lists
NCT02768389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02768389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02768389 about?
NCT02768389 is a clinical study titled "Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma". Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab. This research study involves bevacizumab in combination with a special diet called the Modi...
What is the current status of trial NCT02768389?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2016-09-06. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02768389?
The interventions under investigation include: Bevacizumab (DRUG), Modified Atkins Diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT02768389?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02768389's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI